# ADXN earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/ADXN) · [Earnings tab](https://www.lopjlb.com/stock/ADXN?tab=earnings) Updated: 2026-09-30T07:12:42 Quarters analyzed: 8 ## Cross-quarter narrative Across eight quarterly updates Addex’s story shifted from early financing and program initiation to persistent cash‑runway pressure while maintaining pre‑clinical momentum. Early calls (2024 Q2‑Q3) emphasized a $63 M Neurosterix financing, on‑track GABAB‑PAM and chronic‑cough IND timelines, and modest revenue, but flagged patient‑population uncertainty and dilution risk. By 2024 Q4 the company spun out Neurosterix, reduced burn and disclosed a cash runway only to mid‑2026, heightening financing concerns for unpartnered assets. 2025 quarters repeatedly highlighted strong GABAB‑PAM and dipraglurant data yet underscored that additional capital was required to launch IND‑enabling studies, with cash sufficient only through mid‑2026. 2026 updates showed continued pre‑clinical progress, a low‑burn profile extending runway to Q4 2026‑2027 after an ATM raise, but financing remained “at‑risk” for IND work and a valuation gap on the 20 % Neurosterix stake introduced new equity‑monetisation risk. Throughout, the company’s reliance on Indivior and Neurosterix, regulatory hurdles, and competitive pressures in chronic‑cough and post‑stroke markets persisted, shaping a narrative of scientific advancement constrained by capital limitations. ## Latest CallCard · Q2 Addex Therapeutics highlighted regained GABAB‑PAM rights, progress toward IND filings for SUD and cough, a $2.8 M ATM raise extending cash runway to Q4 2027, pending financing for IND‑enabling studies and a 2044 patent expiry horizon. **Guidance:** vague — No explicit revenue or earnings guidance was provided; only cash runway to Q4 2027 was mentioned. **Tone:** mgmt 0.6 · Q&A pressure 0.4 · divergence 0.3 Prepared remarks emphasized strengthened balance sheet, regained rights and multiple program milestones, conveying optimism. ### Demand visibility Strong unmet medical need for SUD and chronic cough but limited commercial visibility. SUD affects ~17% of U.S. population with ~90% untreated; current cough therapies are ineffective in 30% of patients. ### Capital allocation Raised $2.8 M via ATM to extend runway; seeking additional capital for IND work. ATM facility provides cash runway into Q4 2027; IND‑enabling studies for cough and other programs are pending financing. ### Milestones - **GABAB‑PAM SUD IND filing** [on_track]: IND‑enabling studies completed; ready for IND filing and Phase I. - **GABAB‑PAM chronic cough IND‑enabling start** [at_risk]: Start of IND‑enabling studies pending financing. - **Neurosterix NTX‑253 Phase I data** [on_track]: Phase I data expected in Q4 2026. - **Backup M4 PAM NTX‑529 IND‑enabling** [on_track]: IND‑enabling studies to start shortly. - **mGlu7 NAM NTX‑819 IND‑enabling completion** [on_track]: Expected to complete IND‑enabling studies in coming months. - **Dipraglurant Phase II preparation** [at_risk]: Preparing for Phase II in post‑stroke recovery; financing needed. - **mGlu2 PAM indication evaluation** [new]: Evaluating potential indications and seeking financial resources. - **Patent portfolio expiry** [new]: Patents filed in 2024 expected to expire in 2044. ### Fears / risks - **Financing**: Need to secure additional capital to start IND‑enabling studies for cough and other programs. - **Patent**: Patents are pending; expiration not until 2044, but grant risk remains. - **Therapeutic margin**: Highly potent GABAB‑PAM compounds risk sedation and limited therapeutic window. - **Regulatory**: IND filings and subsequent approvals are uncertain and contingent on financing. - **Partnering**: Future development may depend on securing external partners or licensing deals. - **Market valuation**: Neurosterix equity stake not reflected in current share price, indicating valuation risk. - **Clinical translation**: Preclinical efficacy may not translate to human outcomes. - **Competition**: Limited approved therapies for SUD and cough create both opportunity and competitive pressure. ### Key quotes > “Since our last update, we have seen several important achievements. Firstly, we have strengthened the balance sheet with $2.8 million raised through our ATM facility, which provides us with cash runway into Q4 2027.” > “We expect this program to complete phase I very soon.” ## Quarter one-liners - **2026 Q2:** Addex Therapeutics highlighted regained GABAB‑PAM rights, progress toward IND filings for SUD and cough, a $2.8 M ATM raise extending cash runway to Q4 2027, pending financing for IND‑enabling studies and a 2044 patent expiry horizon. - **2026 Q1:** Addex Therapeutics reports strong preclinical progress on its GABAB cough and dipraglurant brain‑injury programs, low cash burn extending runway to Q4 2026, but notes financing needs for IND work and a valuation gap on its Neurosterix equity. - **2025 Q3:** Addex reported strong preclinical progress on its GABAB PAM cough candidate and dipraglurant for post‑stroke recovery, highlighted Neurosterix advances, but noted financing is needed to start IND studies and cash runs to mid‑2026. - **2025 Q2:** Addex Therapeutics reports strong preclinical data and IND‑enabling completion for its GABAB PAM programs, but highlights cash runway to mid‑2026 and the need for financing to launch its chronic cough IND. - **2025 Q1:** Addex Therapeutics reported strong early‑stage progress on its GABAB PAM programs and dipraglurant repositioning, but highlighted limited cash that does not fund unpartnered IND studies and a need for additional financing. - **2024 Q4:** Addex reported CHF3.3 million cash runway to mid‑2026, highlighted progress on dipraglurant repositioning, GABAB PAM partnership and Neurosterix spin‑out, but noted financing is needed for unpartnered programs. - **2024 Q3:** Addex reports strong preclinical progress on its GABAB PAM programs, IND‑enabling studies slated for early H1 2025, while partnership milestones with Indivior remain undisclosed and Neurosterix cash burn raises dilution concerns. - **2024 Q2:** Addex Therapeutics highlighted a $63M Neurosterix financing, progress on GABAB PAM and chronic cough programs, and plans to start IND‑enabling studies in early H1 2025 while noting modest revenue and FX losses. ## Theme arcs - **Financing & cash runway** (deteriorating): Runway shrank to mid‑2026 then extended to Q4 2027 after ATM raise, but financing gaps for IND work remain. - **GABAB‑PAM program progress** (improving): Pre‑clinical data strengthened, IND filings for SUD on track, chronic‑cough IND‑enabling still at risk. - **Dipraglurant repositioning** (stable): Consistent on‑track status but clinical progression delayed by funding constraints. - **Neurosterix partnership & equity** (new): Spin‑out completed, later equity valuation gap introduced new risk. - **Partner dependence (Indivior)** (stable): Indivior partnership remains central for GABAB‑PAM, with milestone uncertainty recurring. - **Regulatory risk** (stable): Repeated mentions of IND and approval uncertainties across programs. - **Competitive landscape** (stable): Chronic‑cough and M4‑PAM spaces cited as competitive, no change. ## Fear persistence - **Financing risk / cash runway** [recurring]: Repeated need for additional capital to fund IND work and limited runway to mid‑2026/2027. ## Guidance path 2024 Q2:maintained → 2024 Q3:maintained → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:vague → 2026 Q1:maintained → 2026 Q2:vague --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/ADXN`